SCHEMBL6984344

SCHEMBL6984344

CCOC(=O)C1C=Nc2c(ccc3cc(C(=O)Nc4ccc(OCC)cc4)cnc23)C1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P4HTM Q9NXG6 3/20 0.43
KMT2A Q03164 5/20 0.42
MEN1 O00255 4/20 0.42
RAB9A P51151 5/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
MAPT P10636 3/20 0.41
GAA P10253 2/20 0.41
NPC1 O15118 7/20 0.41
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP1A2 P05177 1/20 0.41
TP53 P04637 4/20 0.40
POLB P06746 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
LMNA P02545 2/20 0.40
ABL1 P00519 1/20 0.40
MITF O75030 1/20 0.39
PKM P14618 1/20 0.39
XDH P47989 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6980589 0.92 P4HTM (0.48) P4HTMKMT2AMEN1RAB9ASMN1; SMN2
SCHEMBL6982966 0.82 PSMD14 (0.37) KMT2AMEN1RAB9AMAPTGAA
SCHEMBL7793465 0.76 TP53 (0.36) KMT2AMEN1RAB9AMAPTGAA
SCHEMBL6981271 0.73 HPGD (0.43) KMT2AMEN1SMN1; SMN2MAPTGAA
SCHEMBL6977575 0.70 NPC1 (0.56) P4HTMKMT2AMEN1RAB9ASMN1; SMN2
SCHEMBL6981930 0.69 MAOB (0.43) KMT2ARAB9AMAPTNPC1KDM4E
SCHEMBL6984771 0.68 PSMD14 (0.43) SMN1; SMN2
SCHEMBL7801069 0.68
SCHEMBL7798795 0.68 KMT2A (0.39) KMT2AMEN1RAB9AMAPTGAA
SCHEMBL6982029 0.67 MAOB (0.42) KMT2AMEN1RAB9ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1027351-B1 PHENANTHROLINE DERIVATIVES FIBROGEN INC (US) 2003-12-03 EP disclosed
US-20010001101-A1 Phenanthroline derivatives ZENECA LIMITED 2001-05-10 US disclosed
US-6200974-B1 FOR PRODUCING AN ANTI-FIBROPROLIFERATIVE EFFECT ZENECA LIMITED (GB) 2001-03-13 US disclosed
EP-1027351-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 2000-08-16 EP disclosed
US-5916898-A ANTIFIBROPROLIFERTIVE, ENZYME INHIBITORS OF PYROLYL 4-HYDROXYLASE, ANTIARTHRITIC AGENTS ZENECA LIMITED (GB) 1999-06-29 US disclosed
WO-1999021860-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 1999-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010001101-A1 Phenanthroline derivatives H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, COL1A1, COL2A1 P4HTM 234/4885KMT2A 1250/4885MEN1 2187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.